Endocrinology and Metabolism10.3803/enm.2021.109202136157-59Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 DiabetesJang Won Son,,
Endocrinology and Metabolism10.3803/enm.2020.7812021361157-170Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse ModelJin Hee Kim, Gha Young Lee, Hyo Jin Maeng, Hoyoun Kim, Jae Hyun Bae, Kyoung Min Kim, Soo Lim,,
Diabetes10.2337/db13-07102013631101-110Fibroblast Growth Factor 21 (FGF21) and Glucagon-Like Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor–Deficient MiceBilal A. Omar, Birgitte Andersen, Jacob Hald, Kirsten Raun, Erica Nishimura, Bo Ahrén,
Diabetes, Obesity and Metabolism10.1111/dom.1211920131619-21The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implicationsS. Madsbad,
Diabetes, Obesity and Metabolism10.1111/dom.146402022Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetesChristophe E. M. De Block, Eveline Dirinck, Ann Verhaegen, Luc F. Van Gaal,,
The British Journal of Diabetes & Vascular Disease10.1177/147465140810196120099244-52Review: Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetesNigel Irwin, Marc Moodley, Peter R Flatt,
Canadian Journal of Diabetes10.1016/s1499-2671(09)33334-12009333319Therapeutic potential of glucagon-like peptide-1 agonists in insulin-treated diabetes mellitusJ. Dupre, T.J. McDonald,
Diabetes, Obesity and Metabolism10.1111/j.1463-1326.2010.01313.x201013119-25Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetesJ. Z. Dong, Y. Shen, J. Zhang, N. Tsomaia, D. F. Mierke, J. E. Taylor,
Diabetic Medicine10.1111/j.1466-5468.2004.1180h.x200421s118-20Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of Type 2 diabetesJ. Rachman,
Atherosclerosis10.1016/j.atherosclerosis.2018.06.4492018275e151Fibroblast growth factor 21 serum concentrations in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (DM2).M. Walus-miarka, B. Idzior-Walus, M. Kapusta, A. Trojak, P. Miarka, M.T. Malecki,